Analysis of 514 cases of the treatment of acute herpes zoster in the past 3 years: Relationship between the onset of postherpetic neuralgia and Amenalief® 400 mg

DOI Web Site Web Site 5 References

Bibliographic Information

Other Title
  • 帯状疱疹治療過去３年間514症例の解析：特に帯状疱疹後神経痛の発症とアメナメビルとの関連について
  • タイジョウホウシンチリョウ カコ 3ネンカン 514 ショウレイ ノ カイセキ : トクニ タイジョウホウシンゴ シンケイツウ ノ ハッショウ ト アメナメビル ト ノ カンレン ニ ツイテ

Search this article

Description

To identify a possible relationship between postherpetic neuralgia (PHN) and the medicines used for the treatment of patients with herpes zoster, 495 cases from Sato Dermatology Clinic, in which patients received oral antiviral medicines over the past 3 years, were analyzed; 19 cases of patients with herpes zoster treated orally with Baltrex® granules were excluded from the total 514 cases. In the Baltrex® 3000 mg/day group, which was the control drug group, PHN occurrence was approximately 6.3%, whereas it was approximately 4.9% in the Famvir® 1500 mg/day group and approximately 5.2% in the Amenalief® 400 mg/day group. The same effect in the Baltrex® treatment group was confirmed in the treatment groups orally administered Famvir® and Amenalief®. For these reasons, Amenalief®, which offers the advantages of a single dose per day and does not require consideration of the patient’s renal function, is confirmed to be useful for the treatment for herpes zoster.

Journal

References(5)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top